Business
Curis Announces Three Presentations at SITC 2022
LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for
About this update from Curis, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) being held in Boston, MA and virtually from November 8th to November 12th.\n\n \n \n \n \n \n \n\n \n\"We are pleased to have three posters at SITC this year,\" said James Dentzer, President and Chief Executive Officer of Curis. \"The presentation on emavusertib follows prior research demonstrating emavusertib reaching therapeutic concentrations in brain metastases and how emavusertib might be useful in helping patients with melanoma that has metastasized to the brain by enhancing the effect of anti-PD1 therapy. Two presentations on CI-8993 describe work on our anti-VISTA antibody's pharmacokinetic and pharmacodynamic profile in the clinic and Curis's investigation of potential biomarkers to help guide therapy.\"\nPresentationsEmavusertibAbstract Title: Immune modulation of melanoma brain metastases by IRAK-4 inhibitionAbstract Number: 1111Session Type/Title: Poster/Immune-stimulants and immune modulatorsSession Date and Time: Thursday, November 10, 11:40 a.m.-1:10 p.m. & 7:30 p.m.-9:00 p.m. ETCI-8993Abstract Title: Pharmacokinetic and pharmacodynamic data from a Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid TumorsAbstract Number: 761Session Type/Title: Poster/Clinical Trials in ProgressSession Date and Time: Thursday, November 10, 11:40 a.m.-1:10 p.m. & 7:30 p.m.-9:00 p.m. ETAbstract Title: Development of VISTA-centric tumor immunophenotyping as a novel approach for identification of potential biomarkers for anti-VISTA therapyAbstract Number: 20Session Type/Title: Poster/ Biomarkers, Immune Monitoring and Novel TechnologiesSession Date and Time: Friday, November 11, 11:55 a.m.-1:25 p.m. & 7:00 p.m.-8:30 p.m. ETAbout Emavusertib (CA-4948)Emavusertib is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer. TLRs and the IL-1R family signal through the adaptor protein MYD88, which r...